ArticleNano-micro letters2026
Aggregation-Induced-Emission Luminogens Functionalized MXene Nanosheets for Stimuli-Responsive Hydrogel in Pyroptosis-Mediated Choroidal Melanoma Therapy.
Article in Nano-micro letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Manganese-Chlorella Hydrogel for an Integrated "Remove-Remodel-Repair" Strategy in Pancreatic Cancer Therapy.Nano-micro letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal melanoma is a prevalent intraocular malignant tumor with high mortality rate and liver metastases, related to the lack of sensitive and noninvasive therapeutic modalities. To address the imaging diagnostics and therapeutic predicaments for choroidal melanoma, a novel nanoplatform is developed through the integration of an aggregation-induced emission photosensitizer with two-dimensional MXene nanosheets (MX@PEG-MeoTTPy). This nanoplatform simultaneously exhibits distinctive properties and multiple functions including exceptional biocompatibility, efficient type I reactive oxygen species generation, high-quality fluorescence bioimaging, mild near-infrared (NIR) photothermal performance and superior cellular uptake. Furthermore, a thermosensitive hydrogel composite is engineered to encapsulate the nanosheets, enabling controlled and sustained release over 72 h via NIR irradiation and tumor microenvironment-induced gel-sol transition. The nanoplatform leverages synergistic mild photothermal therapy and photodynamic therapy, leading to precise and sustained tumor ablation through pyroptosis-mediated cell death. Both in vitro and in vivo studies validate that the nanosystem serves as an effective theranostic agent for dual-modal imaging-guided synergistic therapy, offering a multifaceted therapeutic strategy for intraocular tumors and showing significant potential for clinical application in choroidal melanoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.